Q4 2025 and full year 2025 net product revenue of $202.1 million and $677.6 million, respectively –– ARCALYST 2026 net ...
Kiniksa Pharmaceuticals International, plc (KNSA) Q4 2025 Management View Sanj Patel, CEO, stated that "ARCALYST revenue continues to grow, driven by the expanding adoption of IL-1 alpha and beta ...
Phase III study will be "sufficient and pivotal for registration in the U.S." Kiniksa Pharmaceuticals ( KNSA 1.79%) ...
Designed to assess the impact of CardiolRx™ on preventing episodes of recurrent pericarditis, the first patient has been randomized by Northwestern University in Chicago. Based on a successful ...
Recurrent pericarditis occurred in one fifth of patients with systemic lupus erythematosus (SLE), with higher recurrence rates observed in younger patients and those receiving oral prednisone therapy.
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) reported fourth-quarter and full-year 2025 results highlighting continued ...
MAVERIC-2 trial will evaluate the impact of CardiolRx(TM) following cessation of interleukin-1 blocker therapy (rilonacept or anakinra) and is expected to run concurrently with the Company's planned ...
Kiniksa Pharmaceuticals has partnered with country music star Carly Pearce and NHL Hall-of-Famer Henrik Lundqvist to raise awareness about recurrent pericarditis, a chronic heart condition that is ...
Add Yahoo as a preferred source to see more of our stories on Google. The longtime New York Rangers star tells PEOPLE about managing his recurrent pericarditis diagnosis, the autoinflammatory disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results